Predictors of natriuretic peptide non-response in patients hospitalized with acute heart failure

American Journal of Cardiology

Volumn 115, Issue 1, 2015, Pages 69-74

  Ribeiro, Ana ^a   Lourenço, Patrícia ^a,b   Silva, Sérgio ^a,b   Cunha, Francisco ^a   Vilaça, João ^a   Gomes, Filipa ^a   Araújo, José Paulo ^a,b   Bettencourt, Paulo ^a,b  

^a Universidade do Porto   (Portugal)

^b University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BRAIN NATRIURETIC PEPTIDE; CHOLESTEROL; CREATININE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SODIUM; BIOLOGICAL MARKER; NATRIURETIC FACTOR;

ACUTE HEART FAILURE; AGE; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CHRONICITY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG USE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DYSFUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SODIUM BLOOD LEVEL; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; ACUTE DISEASE; BLOOD; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; PREDICTIVE VALUE; PROGNOSIS; REGISTER; TRENDS; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; NATRIURETIC PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84915778641     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.09.053     Document Type: Article

References (30)

1. L.W. Eurlings, P.E. van Pol, W.E. Kok, S. van Wijk, C. Lodewijks-van der Bolt, A.H. Balk, D.J. Lok, H.J. Crijns, D.J. van Kraaij, N. de Jonge, J.G. Meeder, M. Prins, and Y.M. Pinto Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can Pro-Brain-Natriuretic Peptide Guided Therapy of Chronic Heart Failure Improve Heart Failure Morbidity and Mortality?) study J Am Coll Cardiol 56 2010 2090 2100
2. M.R. Shah, R.M. Califf, A. Nohria, M. Bhapkar, M. Bowers, D.M. Mancini, M. Fiuzat, L.W. Stevenson, and C.M. O'Connor The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure J Card Fail 17 2011 613 621
3. H. Persson, H. Erntell, B. Eriksson, G. Johansson, K. Swedberg, and U. Dahlström Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure-SIGNAL-HF (Swedish Intervention study - Guidelines and NT-proBNP Analysis in Heart Failure) Eur J Heart Fail 12 2010 1300 1308
4. P. Karlsrtöm, U. Alehagen, K. Boman, U. Dahlström UPSTEP-Study Group Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome Eur J Heart Fail 13 2013 1096 1103
5. J.G. Lainchbury, R.W. Troughton, K.M. Strangman, C.M. Frampton, A. Pilbrow, T.G. Yandle, A.K. Hamid, M.G. Nicholls, and A.M. Richards N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death) trial J Am Coll Cardiol 55 2009 53 60
6. R.W. Troughton, C.M. Frampton, T.G. Yandle, E.A. Espiner, M.G. Nicholls, and A.M. Richards Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126 1130
7. P. Jourdain, G. Jondeau, F. Funck, P. Gueffet, A. Le Helloco, E. Donal, J.F. Aupetit, M.C. Aumont, M. Galinier, J.C. Eicher, A. Cohen-Solal, and Y. Juillière Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study J Am Coll Cardiol 49 2007 1733 1739
8. R. Berger, D. Moertl, S. Peter, R. Ahmadi, M. Huelsmann, S. Yamuti, B. Wagner, and R. Pacher N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study J Am Coll Cardiol 55 2010 645 653
9. H.K. Gaggin, A.A. Mohammed, A. Bhardwaj, S.U. Rehman, S.A. Gregory, R.B. Weiner, A.L. Baggish, S.A. Moore, M.J. Semigran, and J.L. Januzzi Jr. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study J Card Fail 18 2012 626 634
10. M. Pfisterer, P. Buser, H. Rickli, M. Gutmann, P. Erne, P. Rickenbacher, A. Vuillomenet, U. Jeker, P. Dubach, H. Beer, S.I. Yoon, T. Suter, H.H. Osterhues, M.M. Schieber, P. Hilti, R. Schindler, H.P. Brunner-La Rocca TIME-CHF Investigators BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial JAMA 301 2009 383 392
11. S.R. Motiwala, and J.L. Januzzi Jr. The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure Clin Pharmacol Ther 93 2013 57 67
12. G. Cocco, and P. Jerie Assessing the benefits of natriuretic peptides-guided therapy in chronic heart failure Cardiol J 2014 10.5603/CJ.a2014.0041 [Epub ahead of print]
13. K. Dickstein, A. Cohen-Solal, G. Filippatos, J.J. McMurray, P. Ponikowski, P.A. Poole-Wilson, A. Strömberg, D.J. van Veldhuisen, D. Atar, A.W. Hoes, A. Keren, A. Mebazaa, M. Nieminen, S.G. Priori, K. Swedberg ESC Committee for Practice Guidelines (CPG) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail 10 2008 933 989
14. P.C. Choy, Y.L. Siow, D. Mymin, and K. O Lipids and atherosclerosis Biochem Cell Biol 82 2004 212 224
15. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial Lancet 360 2002 7 22
16. P. Velavan, P. Huan Loh, A. Clark, and J.G. Cleland The cholesterol paradox in heart failure Congest Heart Fail 13 2007 336 341
17. T.B. Horwich, M.A. Hamilton, W.R. Maclellan, and G.C. Fonarow Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure J Card Fail 8 2002 216 224
18. M. Rauchhaus, A.L. Clark, W. Doehner, C. Davos, A. Bolger, R. Sharma, A.J. Coats, and S.D. Anker The relationship between cholesterol and survival in patients with chronic heart failure J Am Coll Cardiol 42 2003 1933 1940
19. S.J. Greene, M. Vaduganathan, L. Lupi, A.P. Ambrosy, R.J. Mentz, M.A. Konstam, S. Nodari, H.P. Subacius, G.C. Fonarow, R.O. Bonow, M. Gheorghiade EVEREST Trial Investigators Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial) Am J Cardiol 111 2013 574 581
20. C.H. Yoon, T.J. Youn, S. Ahn, D.J. Choi, G.Y. Cho, I.H. Chae, J. Choi, H. Cho, S. Han, M.C. Cho, E.S. Jeon, S.C. Chae, J.J. Kim, K.H. Ryu, B.H. Oh Korean Heart Failure Registry Low serum total cholesterol level is a surrogate marker, but not a risk factor, for poor outcome in patients hospitalized with acute heart failure: a report from the Korean Heart Failure Registry J Card Fail 18 2012 194 201
21. M. Christ, T. Klima, W. Grimm, H.H. Mueller, and B. Maisch Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy Eur Heart J 27 2006 691 699
22. B.J. Van Lenten, A.M. Fogelman, M.E. Haberland, and P.A. Edwards The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide Proc Natl Acad Sci U S A 83 1986 2704 2708
23. M. Rauchhaus, A.J. Coats, and S.D. Anker The endotoxin-lipoprotein hypothesis Lancet 356 2000 930 933
24. S.D. Anker, P. Ponikowski, S. Varney, T.P. Chua, A.L. Clark, K.M. Webb-Peploe, D. Harrington, W.J. Kox, P.A. Poole-Wilson, and A.J. Coats Wasting as independent risk factor for mortality in chronic heart failure Lancet 349 1997 1050 1053
25. H. Takeuchi, and M. Sata The relationship among brain natriuretic peptide (BNP), cholesterol and lipoprotein Heart Asia 4 2012 11 15
26. H. Taegtmeyer Metabolic crosstalk in heart failure new roles for B-type natriuretic peptide J Am Coll Cardiol 58 2011 1126 1127
27. J. Polak, M. Kotrc, Z. Wedellova, A. Jabor, I. Malek, J. Kautzner, L. Kazdova, and V. Melenovsky Lipolytic effects of B-type natriuretic peptide 1-32 in adipose tissue of heart failure patients compared with healthy controls J Am Coll Cardiol 58 2011 1119 1125
28. M. Lafontan, C. Moro, M. Berlan, F. Crampes, C. Sengenes, and J. Galitzky Control of lipolysis by natriuretic peptides and cyclic GMP Trends Endocrinol Metab 19 2008 130 137
29. C. Sengenès, M. Berlan, I. De Glisezinski, M. Lafontan, and J. Galitzky Natriuretic peptides: a new lipolytic pathway in human adipocytes FASEB J 14 2000 1345 1351
30. F. Liang, A.M. Kapoun, A. Lam, D.L. Damm, D. Quan, M. O'Connell, and A.A. Protter B-Type natriuretic peptide inhibited angiotensin II-stimulated cholesterol biosynthesis, cholesterol transfer, and steroidogenesis in primary human adrenocortical cells Endocrinology 148 2007 3722 3729